Xcout Intel
RheumaGen, Inc.
RheumaGen, Inc. is a cell and gene therapy company based in Aurora, Colorado, engineering a new class of therapeutics to cure common and major autoimmune diseases such as celiac disease.
Subscribe to see RheumaGen, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
RheumaGen, Inc. at a glance
RheumaGen, Inc. is a cell therapy company headquartered in United States. It has raised at least $22.2M across the 5 funding rounds on record, 4 of them with a disclosed amount. Its most recent funding round, Series A, closed in December 2025. Xcout tracks 11 named people at RheumaGen, Inc., including B Robert Mozayeni (Chief Medical Officer).
RheumaGen, Inc. leadership
- B Robert MozayeniChief Medical Officer
- Ryan HartChief Business and Legal Officer
- Richard FreedCEO and Co-Founder
- Brian HartCOO & Co-Founder
- BRIAN FREEDChief Science Officer & Co-Founder
- Dr. Brian FreedChief Science Officer and Co-Founder
5 more named people on record for RheumaGen, Inc., with roles, board committees and tenure — see the full roster →
RheumaGen, Inc. funding rounds
At least $22.2M raised across the 5 rounds on record (4 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | Undisclosed | 3 named | |
| Series A | $15M | 2 named | |
| SEC Form D filing | $4.9M | — | |
| SEC Form D filing | $300,000 | — | |
| SEC Form D filing | $2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
RheumaGen, Inc. competitors
A few of RheumaGen, Inc.'s closest competitors — see the full list of competitors and alternatives →
Beyond Celiac Investments is an dedicated investment program created by the national organization Beyond Celiac. The initiative is designed to accelerate the development of pharmaceutical treatments and a definitive cure for celiac disease. It bridges patient advocacy with biotech venture funding to fast-track medical research.
Alba Therapeutics Corp. was a U.S. biopharmaceutical company focused on therapies for gastrointestinal and autoimmune disorders. Its lead program was larazotide acetate, an investigational zonulin antagonist intended to help patients with celiac disease by reducing intestinal permeability.
COUR Pharmaceuticals is a clinical-stage biotechnology company headquartered in Evanston, Illinois, founded in 2015. The firm focuses on reprogramming the immune system to develop novel treatments for autoimmune diseases.
GenesisTissue Inc. is a 3D bioprinting tissue company based at the CSU Spur campus in Denver, Colorado. The biotech startup designs and manufactures personalized regenerative tissue implants for humans.
The Celiac Disease Foundation is a non-profit organization dedicated to driving research, education, and advocacy for celiac disease.
Headquartered in South San Francisco, California, Chimera Bioengineering is a privately held biotechnology company focused on developing advanced cellular engineering technologies for cancer therapies.
Get RheumaGen, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on RheumaGen, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access